Why did Concord Biotech (CONCORDBIO) stock move recently?

On 7/29/2026, Concord Biotech moved +5.9% — No clear company-specific catalyst identified in recent filings or credible news coverage for the July 29 move; the stock rose alongside broader market or sector trends ahead of the scheduled July 31 board meeting. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Concord Biotech (CONCORDBIO) overvalued or fairly valued?

MarketChacha shows Concord Biotech's valuation in context — a forward P/E of about 33.6, a price-to-book of about 7.4 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Concord Biotech's revenue?

Concord Biotech reported revenue of ₹1,055 Cr for FY2026, with net profit of ₹263 Cr, per official filings.

What is the share price of Concord Biotech (CONCORDBIO)?

Concord Biotech last traded at ₹1,428.90 (+0.7% on the day), as of 8/11/2026 — a delayed quote shown for education, not investment advice.

Concord Biotech

CONCORDBIO · NSE · Pharma · India

Snapshot

TickerCONCORDBIO

ExchangeNSE

SectorPharma

IndustryBiotechnology

CountryIndia

Employees1,624

HeadquartersAhmedabad, India

Websitewww.concordbiotech.com

Filings tracked6

About Concord Biotech

Concord Biotech Limited, a, biopharma company, engages in the research and development, manufacture, and sale of pharmaceutical products in India and internationally. It operates through Active Pharmaceutical Ingredients (APIs) and Formulations segments. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, daptomycin, fusidic acid, colistimethate sodium, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi acetate, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

Who owns it

Promoters72.5%
Institutions12.8%
Public & other14.7%

47 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

Margin has compressed by about 5.3 points over the period — profitability is trending down.

Net margin trend30.3% → 25.0%

Margin has compressed by about 5.3 points over the period — profitability is trending down.

Growth qualityrev 2% · PAT 3%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (BSE (official results filing)). Education, not a rating or recommendation.

What's expected next

Next fiscal year

Rev ₹1,572 Cr · EPS 42.54

Est. earnings growth +30.3%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: BSE (official results filing)

Annual

Quarterly · last 5

Revenue (FY2026)

₹1,055 Cr

Net margin

25.0%

Revenue CAGR (2y)

+1.9%

Profit CAGR (3y)

+3.1%

EPS (FY2026)

25.17

Net profit (FY2026)

₹263 Cr

Ask MarketChacha about CONCORDBIO

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 29, 2026
No clear company-specific catalyst identified in recent filings or credible news coverage for the July 29 move; the stock rose alongside broader market or sector trends ahead of the scheduled July 31 board meeting.
· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin
FY2026	₹1,055 Cr	₹263 Cr	25.17	25.0%
FY2025	₹1,200 Cr	₹372 Cr	—	31.0%
FY2024	₹1,017 Cr	₹308 Cr	—	30.3%
FY2023	—	₹240 Cr	—	—

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	₹261 Cr	₹61 Cr	5.85	23.5%
2026Q1	₹326 Cr	₹90 Cr	8.60	27.6%
2025Q4	₹278 Cr	₹68 Cr	6.48	24.4%
2025Q3	₹247 Cr	₹64 Cr	—	25.7%
2025Q2	₹204 Cr	₹44 Cr	—	21.6%

Figures as reported, in ₹ (crore). Source: BSE (official results filing).

Filings & announcements

2026

Investor Presentation
Investors'' Presentation on unaudited Standalone and Consolidated Financial Results for the first quarter ended June 30, 2026
BSE8/1/2026
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Pursuant to regulation 44(3) of the SEBI (LODR) Regulations, 2015 and section 108 of the Companies Act, 2013, the voting results along with the scrutinizers report for the business items ....
BSE8/1/2026material
Shareholder Meeting / Postal Ballot-Outcome of AGM
The 41st Annual General Meeting Meeting of the Members of the Company was held on Friday July, 31, 2026 at 12:00 Noon through VC/OAVM. The summary of the proceedings are published herewith.
BSE7/31/2026material
Unaudited Standalone And Consolidated Financial Results For The First Quarter Ended On June 30, 2026
Unaudited Standalone and Consolidated Financial Results for the first quarter ended on June 30, 2026
BSE7/31/2026
Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. Friday, July 31, 2026 - Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
We would like to inform you that the Board of Directors of the Company, at its meeting held today i.e. Friday, July 31, 2026, on review and recommendation of Audit Committee of the Company, ....
BSE7/31/2026
Board Meeting Intimation for Meeting To Be Held On Friday, July 31, 2026
Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2026 ,inter alia, to consider and approve the unaudited Standalone and ....
BSE7/28/2026material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.